Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CORT

Corcept Therapeutics Inc

Feb 06 • 04:00PM ET

40.83

+2.47 6.44 %

Healthcare • Biotechnology • USA • NASD

Peers: NBIX SRPT TGTX MDGL ARDX ANAB VKTX AKBA LGND PSTV

| Held by: IJR VTI FBT VB VBK VXF SPSM IJT IWP XSMO

Index	-	P/E	46.65	EPS (ttm)	0.88	Insider Own	11.82%	Shs Outstand	105.12M	Perf Week	2.41%
Market Cap	4.29B	Forward P/E	67.26	EPS next Y	0.61	Insider Trans	-3.33%	Shs Float	92.76M	Perf Month	10.35%
Enterprise Value	3.88B	PEG	2.07	EPS next Q	0.33	Inst Own	73.87%	Short Float	8.83%	Perf Quarter	-46.73%
Income	104.65M	P/S	5.79	EPS this Y	-22.28%	Inst Trans	-1.40%	Short Ratio	4.50	Perf Half Y	-42.88%
Sales	741.17M	P/B	6.79	EPS next Y	-36.50%	ROA	13.02%	Short Interest	8.19M	Perf YTD	17.33%
Book/sh	6.01	P/C	10.19	EPS next 5Y	32.54%	ROE	16.47%	52W High	117.33 -65.20%	Perf Year	-40.35%
Cash/sh	4.01	P/FCF	26.42	EPS past 3/5Y	11.29% 9.89%	ROIC	16.42%	52W Low	32.99 23.76%	Perf 3Y	70.55%
Dividend Est.	-	EV/EBITDA	57.53	Sales past 3/5Y	22.64% 17.11%	Gross Margin	98.19%	Volatility	5.60% 5.51%	Perf 5Y	39.40%
Dividend TTM	-	EV/Sales	5.23	EPS Y/Y TTM	-26.13%	Oper. Margin	8.85%	ATR (14)	3.25	Perf 10Y	1018.63%
Dividend Ex-Date	-	Quick Ratio	3.07	Sales Y/Y TTM	17.92%	Profit Margin	14.12%	RSI (14)	40.05	Recom	1.86
Dividend Gr. 3/5Y	- -	Current Ratio	3.14	EPS Q/Q	-60.52%	SMA20	2.31%	Beta	0.28	Target Price	94.20
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	13.75%	SMA50	-31.85%	Rel Volume	0.72	Prev Close	38.36
Employees	500	LT Debt/Eq	0.01	Earnings	Nov 04 AMC	SMA200	-41.91%	Avg Volume	1.82M	Price	40.83
IPO	Apr 14, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.26% -6.96%	Trades		Volume	1,309,620	Change	6.44%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-31-25	Downgrade	Wolfe Research	Peer Perform → Underperform	$30
Dec-16-25	Initiated	UBS	Neutral
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-06-23	Upgrade	Truist	Hold → Buy	$29 → $38
Apr-11-23	Initiated	SVB Securities	Market Perform	$25
Apr-04-23	Initiated	Piper Sandler	Overweight	$27
Feb-15-23	Downgrade	Jefferies	Buy → Hold	$35 → $22
Aug-01-22	Downgrade	Truist	Buy → Hold	$30
Jul-27-22	Upgrade	Jefferies	Hold → Buy	$21 → $35
Jun-27-22	Resumed	Canaccord Genuity	Buy	$30 → $34
Feb-02-22	Initiated	Canaccord Genuity	Buy	$30
Jan-28-22	Initiated	Truist	Buy	$30
Aug-05-20	Downgrade	Jefferies	Buy → Hold	$16
Sep-24-19	Initiated	Jefferies	Buy	$20
Sep-06-19	Initiated	H.C. Wainwright	Buy	$18
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral	$22 → $12
Aug-10-18	Reiterated	Stifel	Hold	$20 → $11
May-31-18	Downgrade	Stifel	Buy → Hold	$20
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy	$30
Aug-31-17	Initiated	Stifel	Buy	$20

Show Previous Ratings

Feb-04-26 03:31PM	Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile)
Jan-30-26 08:32PM	Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing (Business Wire) -10.63%
Jan-25-26 06:44PM	Corcept Therapeutics (CORT) Climbs 26.6% on Stellar Clinical Trial Result (Insider Monkey)
Jan-23-26 01:55PM	Silver Breaks $101, Intel Stock Plunges 17%: What's Moving Markets Friday? (Benzinga) +6.49%
11:13AM	CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study (Zacks)
08:11AM	Loading…
08:11AM	Corcept Therapeutics (CORT) Climbs 13.7% on Strong Clinical Trial Results (Insider Monkey)
05:27AM	Novo climbs higher on strong Wegovy pill launch; Terns tweaks leukemia drug deal (BioPharma Dive)
Jan-22-26 04:05PM	Why Former Highflier Corcept Therapeutics Just Surged Again (Investor's Business Daily) +13.74%
03:06PM	Russell 2000 Extends Records, Meta Jumps 5%: What's Moving Markets Thursday? (Benzinga)
01:07PM	Corcepts stock up as relacorilant meets OS goal in Phase III ovarian cancer trial (Clinical Trials Arena)
11:12AM	Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps (Benzinga)
08:00AM	Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Jan-15-26 08:15AM	Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts? (Insider Monkey)
06:47AM	One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit (24/7 Wall St.)
Jan-14-26 11:56AM	Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman (PR Newswire)
03:16AM	Loading…
Jan-09-26 03:16AM	Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter (Insider Monkey)
Jan-06-26 12:01PM	Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman (PR Newswire)
Jan-05-26 11:31PM	1 Healthcare Stock to Target This Week and 2 We Turn Down (StockStory) -8.51%
12:16PM	Why Corcept (CORT) Stock Is Trading Lower Today (StockStory)
09:54AM	Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Jan-02-26 11:17AM	The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away (Barchart) +9.77%
10:22AM	Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism (Zacks)
08:50AM	Implied Volatility Surging for Corcept Stock Options (Zacks)
07:30AM	Company News for Jan 2, 2026 (Zacks)
Jan-01-26 08:10AM	FDA says it needs additional evidence of effectiveness for Corcept relacorilant (TipRanks)
Dec-31-25 06:41PM	Why Corcept Therapeutics Plummeted by 50% Today (Motley Fool) -50.42% +9.77%
05:00PM	Why Corcept (CORT) Shares Are Falling Today (StockStory)
04:34PM	Stocks Settle Lower on Tech Weakness and Higher Bond Yields (Barchart)
12:31PM	Corcept Therapeutics Shares Plunge 50% After FDA Rejects Blood Pressure Drug (Barrons.com)
10:00AM	Corcept Sinks After FDA Rejects Drug to Treat Hypertension (Bloomberg)
09:57AM	Loading…
09:57AM	Stocks Slide on Weakness in Megacap Tech Stocks (Barchart)
08:00AM	Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism (Business Wire)
Dec-30-25 06:32AM	Stock Market Today: Stocks Struggling to Finish 2025 on High Note (TheStreet) -12.06%
Dec-23-25 03:51PM	Why Corcept (CORT) Stock Is Trading Lower Today (StockStory)
Dec-21-25 08:56AM	Corcept Therapeutics (CORT): Analyst Says Shares Pricing in Growth, New Launch (Insider Monkey)
Dec-16-25 11:03PM	Corcept (CORT): Buy, Sell, or Hold Post Q3 Earnings? (StockStory) -7.08%
02:05PM	Why Corcept (CORT) Stock Is Down Today (StockStory)
Dec-11-25 07:44AM	Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects (Insider Monkey)
Dec-10-25 11:30AM	Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-07-25 10:33PM	Analysts See 70% Upside Potential in Corcept Therapeutics (CORT) Stock (Insider Monkey)
Dec-04-25 11:30AM	Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-01-25 11:04AM	Will Korlym Continue to Drive Corcept's Top Line in 2026? (Zacks)
Nov-26-25 02:59PM	Corcept Therapeutics Incorporated (CORT) Modifies Revenue Guidance while Banking on Cushing Syndrome Treatment for Growth (Insider Monkey)
Nov-12-25 10:34PM	Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT) (StockStory)
Nov-11-25 12:36AM	The 5 Most Interesting Analyst Questions From Corcept's Q3 Earnings Call (StockStory)
Nov-05-25 10:01AM	Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down (Zacks) +7.81%
08:31AM	CORT Q3 Deep Dive: Pharmacy Transition and Pipeline Expansion Drive Mixed Outlook (StockStory)
12:10AM	Corcept Therapeutics Inc (CORT) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Net ... (GuruFocus.com)
Nov-04-25 06:25PM	Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates (Zacks)
06:00PM	Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q3 Earnings (StockStory)
05:20PM	Corcept: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update (Business Wire)
09:36AM	What Does Wall Street Think About Corcept Therapeutics (CORT)? (Insider Monkey)
Nov-02-25 10:04PM	Corcept Earnings: What To Look For From CORT (StockStory)
Oct-29-25 10:00AM	NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 04:05PM	Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Oct-22-25 10:00AM	Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-19-25 05:15AM	Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment (Business Wire)
Oct-17-25 09:54PM	H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) (Insider Monkey)
Oct-15-25 02:02PM	Corcept (CORT) Shares Skyrocket, What You Need To Know (StockStory) +6.50%
11:35AM	CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer (Zacks)
Oct-14-25 08:00AM	Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Oct-10-25 11:51AM	Why Corcept (CORT) Shares Are Falling Today (StockStory) -16.30%
Oct-03-25 08:21AM	Here's What Makes Corcept Therapeutics (CORT) an Attractive Investment? (Insider Monkey)
Oct-01-25 04:01PM	Why Corcept (CORT) Stock Is Trading Up Today (StockStory)
10:40AM	Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym? (Zacks)
Sep-29-25 07:20PM	Corcept Therapeutics Beats Q2 Estimates, Cuts Guidance and Advances NDA for New Cancer Drug (Insider Monkey)
Sep-24-25 04:06AM	FDA Accepts New Drug Application for Corcept Therapeutics's (CORT) Relacorilant (Insider Monkey)
Sep-23-25 03:25PM	Why Are Corcept (CORT) Shares Soaring Today (StockStory)
Sep-22-25 02:30PM	Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 (Business Wire)
Sep-16-25 12:02AM	Corcept (CORT): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Sep-15-25 11:36PM	Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment (StockStory)
02:18PM	11 fast-growing small-cap stocks that could get a boost from the Fed's next move (MarketWatch)
Sep-11-25 11:57AM	FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer (Zacks)
03:31AM	Corcept's (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint (Insider Monkey)
Sep-10-25 08:00AM	FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Sep-02-25 09:58AM	Can Korlym Drive Corcept's Growth Through the Rest of 2025? (Zacks)
Aug-25-25 02:03PM	Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock? (Zacks)
Aug-22-25 11:57PM	Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT (Insider Monkey)
Aug-13-25 12:25AM	5 Must-Read Analyst Questions From Corcept's Q2 Earnings Call (StockStory)
12:00AM	CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook (StockStory)
Aug-01-25 12:04PM	CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down (Zacks)
Jul-31-25 05:35PM	Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates (Zacks)
05:27PM	Corcept (NASDAQ:CORT) Misses Q2 Sales Targets (StockStory)
04:36PM	Corcept: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update (Business Wire)
Jul-29-25 11:05PM	What To Expect From Corcept's (CORT) Q2 Earnings (StockStory)
Jul-28-25 02:07AM	H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) (Insider Monkey)
Jul-27-25 09:58AM	Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk (Insider Monkey)
Jul-24-25 11:48PM	Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant (Insider Monkey)
04:05PM	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Jul-23-25 11:00AM	Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects (Insider Monkey)
Jul-17-25 07:10AM	Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? (Zacks)
12:08AM	3 Reasons CORT is Risky and 1 Stock to Buy Instead (StockStory)
Jul-15-25 10:17AM	Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer (Zacks)
Jul-14-25 08:00AM	Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Jul-06-25 04:15AM	Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial (Insider Monkey)
Jul-04-25 01:48AM	Corcept Therapeutics' Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients (Insider Monkey)
Jun-30-25 06:20AM	Should Invesco S&P SmallCap Momentum ETF (XSMO) Be on Your Investing Radar? (Zacks)
Jun-27-25 08:56AM	Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guyer William	Chief Development Officer	Feb 03 '26	Option Exercise	21.65	20,000	433,000	21,235	Feb 05 05:42 PM
Guyer William	Chief Development Officer	Feb 03 '26	Sale	40.87	20,000	817,334	1,235	Feb 05 05:42 PM
Guyer William	Officer	Feb 03 '26	Proposed Sale	40.71	20,000	814,200		Feb 03 11:26 AM
BAKER G LEONARD JR	Director	Jan 27 '26	Option Exercise	11.49	140,000	1,608,700	1,095,262	Jan 29 04:10 PM
Guyer William	Chief Development Officer	Jan 06 '26	Option Exercise	21.65	20,000	433,000	21,235	Jan 08 08:35 PM
Guyer William	Chief Development Officer	Jan 06 '26	Sale	35.18	20,000	703,656	1,235	Jan 08 08:35 PM
Guyer William	Officer	Jan 06 '26	Proposed Sale	34.95	20,000	699,000		Jan 06 12:04 PM
Robb Gary Charles	Chief Business Officer	Dec 24 '25	Option Exercise	3.88	145,000	562,600	158,910	Dec 29 05:58 PM
BELANOFF JOSEPH K	Chief Executive Officer	Dec 24 '25	Option Exercise	3.88	550,000	2,134,000	550,000	Dec 29 05:24 PM
Guyer William	Chief Development Officer	Dec 02 '25	Option Exercise	21.65	20,000	433,000	21,235	Dec 03 09:19 PM
Guyer William	Chief Development Officer	Dec 02 '25	Sale	80.08	20,000	1,601,526	1,235	Dec 03 09:19 PM
Maduck Sean	See Remarks	Dec 01 '25	Option Exercise	8.27	20,000	165,400	27,904	Dec 03 08:53 PM
Maduck Sean	See Remarks	Dec 01 '25	Sale	79.52	20,000	1,590,490	7,904	Dec 03 08:53 PM
Lyon Joseph Douglas	See Remarks	Dec 01 '25	Option Exercise	13.56	5,000	67,800	15,277	Dec 03 08:36 PM
Lyon Joseph Douglas	See Remarks	Dec 01 '25	Sale	79.53	5,000	397,632	10,277	Dec 03 08:36 PM
BELANOFF JOSEPH K	Chief Executive Officer	Dec 01 '25	Sale	79.77	40,000	3,190,796	2,701,370	Dec 03 08:14 PM
Guyer William	Officer	Dec 02 '25	Proposed Sale	79.78	20,000	1,595,600		Dec 02 10:34 AM
BELANOFF JOSEPH K	Officer	Dec 01 '25	Proposed Sale	79.40	40,000	3,176,000		Dec 01 02:36 PM
Maduck Sean	Officer	Dec 01 '25	Proposed Sale	79.40	20,000	1,588,000		Dec 01 02:00 PM
Lyon Joseph Douglas	Officer	Dec 01 '25	Proposed Sale	79.40	5,000	397,000		Dec 01 01:50 PM
Guyer William	Chief Development Officer	Nov 25 '25	Sale	80.90	4,500	364,070	787	Nov 26 05:22 PM
Guyer William	Officer	Nov 25 '25	Proposed Sale	80.90	4,500	364,070		Nov 25 04:46 PM
Guyer William	Chief Development Officer	Nov 05 '25	Option Exercise	21.65	20,000	433,000	25,287	Nov 07 05:10 PM
Guyer William	Chief Development Officer	Nov 05 '25	Sale	75.36	20,000	1,507,122	5,287	Nov 07 05:10 PM
Lyon Joseph Douglas	See Remarks	Nov 03 '25	Option Exercise	13.56	5,000	67,800	15,277	Nov 05 07:59 PM
Lyon Joseph Douglas	See Remarks	Nov 03 '25	Sale	73.65	5,000	368,244	10,277	Nov 05 07:59 PM
BELANOFF JOSEPH K	Chief Executive Officer	Nov 05 '25	Sale	74.77	28,782	2,152,105	2,741,370	Nov 05 07:57 PM
BELANOFF JOSEPH K	Chief Executive Officer	Nov 03 '25	Sale	74.08	11,218	831,014	2,770,152	Nov 05 07:57 PM
Maduck Sean	See Remarks	Nov 03 '25	Option Exercise	8.27	20,000	165,400	27,904	Nov 05 07:56 PM
Maduck Sean	See Remarks	Nov 03 '25	Sale	73.99	20,000	1,479,816	7,904	Nov 05 07:56 PM
Guyer William	Officer	Nov 05 '25	Proposed Sale	71.10	20,000	1,422,000		Nov 05 10:12 AM
BELANOFF JOSEPH K	Officer	Nov 03 '25	Proposed Sale	73.47	40,000	2,938,800		Nov 03 04:06 PM
Lyon Joseph Douglas	Officer	Nov 03 '25	Proposed Sale	73.47	5,000	367,350		Nov 03 03:31 PM
Maduck Sean	Officer	Nov 03 '25	Proposed Sale	73.47	20,000	1,469,400		Nov 03 03:25 PM
Swisher Daniel N JR	Director	Oct 10 '25	Option Exercise	14.08	2,200	30,976	2,200	Oct 15 06:31 PM
Swisher Daniel N JR	Director	Oct 10 '25	Sale	87.54	2,200	192,588	0	Oct 15 06:31 PM
Swisher Daniel N JR	Director	Oct 10 '25	Proposed Sale	87.54	2,200	192,588		Oct 10 10:44 AM
Guyer William	Chief Development Officer	Oct 07 '25	Option Exercise	21.65	20,000	433,000	25,287	Oct 09 05:51 PM
Guyer William	Chief Development Officer	Oct 07 '25	Sale	89.94	20,000	1,798,782	5,287	Oct 09 05:51 PM
Guyer William	Officer	Oct 07 '25	Proposed Sale	89.85	20,000	1,797,000		Oct 07 01:51 PM
BELANOFF JOSEPH K	Chief Executive Officer	Oct 01 '25	Sale	85.08	40,000	3,403,253	2,781,370	Oct 03 05:24 PM
Lyon Joseph Douglas	See Remarks	Oct 01 '25	Option Exercise	13.56	5,000	67,800	15,277	Oct 03 05:17 PM
Lyon Joseph Douglas	See Remarks	Oct 01 '25	Sale	84.75	5,000	423,766	10,277	Oct 03 05:17 PM
Maduck Sean	See Remarks	Oct 01 '25	Option Exercise	7.95	20,000	159,005	27,904	Oct 03 05:15 PM
Maduck Sean	See Remarks	Oct 01 '25	Sale	85.06	20,000	1,701,232	7,904	Oct 03 05:15 PM
BELANOFF JOSEPH K	Officer	Oct 01 '25	Proposed Sale	83.11	40,000	3,324,400		Oct 01 03:34 PM
Maduck Sean	Officer	Oct 01 '25	Proposed Sale	83.11	20,000	1,662,200		Oct 01 01:54 PM
Lyon Joseph Douglas	Officer	Oct 01 '25	Proposed Sale	83.11	5,000	415,550		Oct 01 01:42 PM
Swisher Daniel N JR	Director	Sep 10 '25	Option Exercise	14.08	2,200	30,976	2,200	Sep 11 08:38 PM
Swisher Daniel N JR	Director	Sep 10 '25	Sale	72.45	2,200	159,390	0	Sep 11 08:38 PM
Swisher Daniel N JR	Director	Sep 10 '25	Proposed Sale	72.45	2,200	159,390		Sep 10 09:50 AM
Cannon Gillian	Director	Sep 04 '25	Option Exercise	22.99	11,000	252,890	11,000	Sep 08 08:20 PM
Guyer William	Chief Development Officer	Sep 02 '25	Option Exercise	21.65	20,000	433,000	25,487	Sep 04 07:59 PM
Guyer William	Chief Development Officer	Sep 02 '25	Sale	70.49	20,000	1,409,848	5,487	Sep 04 07:59 PM
Lyon Joseph Douglas	See Remarks	Sep 02 '25	Option Exercise	13.56	5,000	67,800	15,066	Sep 04 07:56 PM
Lyon Joseph Douglas	See Remarks	Sep 02 '25	Sale	70.25	5,000	351,247	10,066	Sep 04 07:56 PM
Maduck Sean	See Remarks	Sep 02 '25	Option Exercise	5.05	20,000	101,000	27,681	Sep 04 07:54 PM
Maduck Sean	See Remarks	Sep 02 '25	Sale	70.49	20,000	1,409,828	7,681	Sep 04 07:54 PM
BELANOFF JOSEPH K	Chief Executive Officer	Sep 02 '25	Sale	70.53	40,000	2,821,033	2,821,370	Sep 04 07:54 PM
Guyer William	Officer	Sep 02 '25	Proposed Sale	69.72	20,000	1,394,400		Sep 02 04:31 PM
Maduck Sean	Officer	Sep 02 '25	Proposed Sale	69.72	20,000	1,394,400		Sep 02 04:23 PM
Lyon Joseph Douglas	Officer	Sep 02 '25	Proposed Sale	69.72	5,000	348,600		Sep 02 04:16 PM
BELANOFF JOSEPH K	Officer	Sep 02 '25	Proposed Sale	69.72	40,000	2,788,800		Sep 02 04:09 PM
Robb Gary Charles	Chief Business Officer	Aug 22 '25	Option Exercise	3.88	5,000	19,400	18,364	Aug 26 06:56 PM
Robb Gary Charles	Chief Business Officer	Aug 22 '25	Sale	71.27	2,326	165,774	16,038	Aug 26 06:56 PM
Robb Gary Charles	Officer	Aug 22 '25	Proposed Sale	71.27	2,326	165,774		Aug 22 10:58 AM
Swisher Daniel N JR	Director	Aug 11 '25	Option Exercise	14.08	2,200	30,976	2,200	Aug 12 07:22 PM
Swisher Daniel N JR	Director	Aug 11 '25	Sale	72.30	2,200	159,060	0	Aug 12 07:22 PM
Guyer William	Chief Development Officer	Aug 08 '25	Option Exercise	21.65	35,007	757,902	40,494	Aug 12 07:19 PM
Guyer William	Chief Development Officer	Aug 08 '25	Sale	71.77	35,007	2,512,452	5,487	Aug 12 07:19 PM
Swisher Daniel N JR	Director	Aug 11 '25	Proposed Sale	72.30	2,200	159,060		Aug 11 10:20 AM
Guyer William	Chief Development Officer	Aug 05 '25	Option Exercise	21.65	14	303	5,501	Aug 07 07:17 PM
Guyer William	Chief Development Officer	Aug 05 '25	Sale	71.77	14	1,005	5,487	Aug 07 07:17 PM
Maduck Sean	See Remarks	Aug 01 '25	Option Exercise	5.05	35,007	176,785	42,688	Aug 05 06:51 PM
Maduck Sean	See Remarks	Aug 01 '25	Sale	67.79	35,007	2,373,237	7,681	Aug 05 06:51 PM
BELANOFF JOSEPH K	Chief Executive Officer	Aug 01 '25	Sale	68.53	40,000	2,741,207	2,861,370	Aug 05 06:51 PM
Lyon Joseph Douglas	See Remarks	Aug 01 '25	Option Exercise	13.56	5,823	78,960	15,889	Aug 05 06:47 PM
Lyon Joseph Douglas	See Remarks	Aug 01 '25	Sale	67.51	5,823	393,128	10,066	Aug 05 06:47 PM
Guyer William	Officer	Aug 05 '25	Proposed Sale	71.77	20,000	1,435,400		Aug 05 01:05 PM
Lyon Joseph Douglas	Officer	Aug 01 '25	Proposed Sale	67.17	5,000	335,850		Aug 01 11:25 AM
Maduck Sean	Officer	Aug 01 '25	Proposed Sale	67.15	20,000	1,343,000		Aug 01 11:11 AM
BELANOFF JOSEPH K	Officer	Aug 01 '25	Proposed Sale	67.17	615	41,310		Aug 01 11:00 AM
Maduck Sean	See Remarks	Jul 17 '25	Option Exercise	5.05	4,315	21,791	22,020	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 18 '25	Option Exercise	5.05	473	2,389	18,178	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 17 '25	Sale	73.48	4,315	317,054	17,705	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 18 '25	Sale	73.44	473	34,737	17,705	Jul 21 07:14 PM
BELANOFF JOSEPH K	Chief Executive Officer	Jul 17 '25	Sale	73.69	615	45,318	2,901,370	Jul 21 07:11 PM
Lyon Joseph Douglas	See Remarks	Jul 17 '25	Option Exercise	13.56	3,877	52,572	13,943	Jul 21 07:10 PM
Lyon Joseph Douglas	See Remarks	Jul 18 '25	Option Exercise	13.56	200	2,712	10,266	Jul 21 07:10 PM
Lyon Joseph Douglas	See Remarks	Jul 17 '25	Sale	73.48	3,877	284,864	10,066	Jul 21 07:10 PM
Lyon Joseph Douglas	See Remarks	Jul 18 '25	Sale	73.40	200	14,680	10,066	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 17 '25	Option Exercise	21.65	4,379	94,805	9,866	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 18 '25	Option Exercise	21.65	500	10,825	5,987	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 17 '25	Sale	73.48	4,379	321,774	5,487	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 18 '25	Sale	73.44	500	36,721	5,487	Jul 21 07:10 PM
BELANOFF JOSEPH K	Officer	Jul 17 '25	Proposed Sale	72.85	40,000	2,914,000		Jul 17 04:00 PM
Swisher Daniel N JR	Director	Jul 10 '25	Option Exercise	14.08	2,200	30,976	2,200	Jul 14 04:36 PM
Swisher Daniel N JR	Director	Jul 10 '25	Sale	71.08	2,200	156,376	0	Jul 14 04:36 PM
Swisher Daniel N JR	Director	Jul 10 '25	Proposed Sale	71.08	2,200	156,376		Jul 10 12:21 PM
Guyer William	Chief Development Officer	Jul 01 '25	Option Exercise	21.65	100	2,165	5,587	Jul 03 08:39 PM

Open in Screener

CERS

Cerus Corp

Feb 06 • 04:00PM ET

2.20

+0.06 2.80 %

Healthcare • Medical Devices • USA • NASD

Peers: QDEL BIO HCSG AEMD ARWR AXDX MMSI FATE INSP XERS

| Held by: ARKK ARKG VTI IWM VXF IWO SCHA FESM VTWO SMLF

Index	RUT	P/E	-	EPS (ttm)	-0.08	Insider Own	4.74%	Shs Outstand	192.04M	Perf Week	-5.58%
Market Cap	422.59M	Forward P/E	-	EPS next Y	-0.04	Insider Trans	-0.33%	Shs Float	182.98M	Perf Month	5.26%
Enterprise Value	443.01M	PEG	-	EPS next Q	-0.01	Inst Own	73.97%	Short Float	3.90%	Perf Quarter	51.72%
Income	-15.96M	P/S	2.12	EPS this Y	28.36%	Inst Trans	-0.73%	Short Ratio	4.78	Perf Half Y	77.42%
Sales	199.19M	P/B	6.87	EPS next Y	50.48%	ROA	-7.89%	Short Interest	7.14M	Perf YTD	6.80%
Book/sh	0.32	P/C	5.38	EPS next 5Y	-	ROE	-27.78%	52W High	2.95 -25.55%	Perf Year	17.02%
Cash/sh	0.41	P/FCF	2485.82	EPS past 3/5Y	29.07% 25.97%	ROIC	-13.22%	52W Low	1.12 96.43%	Perf 3Y	-31.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	11.27% 13.96%	Gross Margin	55.19%	Volatility	7.10% 6.96%	Perf 5Y	-67.46%
Dividend TTM	-	EV/Sales	2.22	EPS Y/Y TTM	21.28%	Oper. Margin	-18.21%	ATR (14)	0.15	Perf 10Y	-59.48%
Dividend Ex-Date	-	Quick Ratio	1.29	Sales Y/Y TTM	13.03%	Profit Margin	-8.01%	RSI (14)	45.12	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.89	EPS Q/Q	99.37%	SMA20	-8.90%	Beta	1.54	Target Price	4.67
Payout	-	Debt/Eq	1.60	Sales Q/Q	14.52%	SMA50	1.18%	Rel Volume	0.85	Prev Close	2.14
Employees	281	LT Debt/Eq	0.97	Earnings	Nov 06 AMC	SMA200	37.99%	Avg Volume	1.49M	Price	2.20
IPO	Jan 31, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	100.00% 4.18%	Trades		Volume	1,263,630	Change	2.80%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-24	Initiated	Craig Hallum	Buy	$5
Jan-20-23	Downgrade	BTIG Research	Buy → Neutral
Jan-17-23	Downgrade	Stephens	Overweight → Equal-Weight	$3.75
Oct-08-20	Resumed	BTIG Research	Buy	$9
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$9
Feb-26-20	Initiated	BTIG Research	Buy	$7
Nov-13-19	Upgrade	BTIG Research	Neutral → Buy	$7
Aug-28-19	Initiated	Stifel	Buy
Aug-23-19	Resumed	Stephens	Overweight
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Dec-08-17	Resumed	BTIG Research	Neutral
Jul-07-16	Resumed	Cantor Fitzgerald	Buy	$9
Dec-17-15	Downgrade	Wedbush	Outperform → Neutral
May-02-14	Reiterated	MLV & Co	Buy	$8.50 → $6
Apr-24-13	Reiterated	Cantor Fitzgerald	Buy	$5.50 → $6
Mar-15-13	Reiterated	MLV & Co	Buy	$7.50 → $8.50
Apr-17-12	Initiated	Cantor Fitzgerald	Buy	$5.50
Feb-29-12	Upgrade	Robert W. Baird	Neutral → Outperform	$3 → $6
Nov-10-11	Reiterated	MLV & Co	Buy	$4 → $5
Jun-03-11	Initiated	Wedbush	Outperform	$4

Show Previous Ratings

Jan-22-26 07:30AM	DRK Blood Donation Service Baden-Wurttemberg - Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT Blood System in Routine Clinical Practice (Business Wire)
Jan-11-26 04:00PM	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook (Business Wire)
Dec-27-25 07:43AM	TD Cowen Sees Compelling Long-Term Value in Cerus Corporation (CERS) (Insider Monkey)
Dec-10-25 04:15PM	Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America (Business Wire) +13.76%
Nov-07-25 12:01AM	Cerus Corp (CERS) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Shifts Amid ... (GuruFocus.com) +21.28%
05:07PM	Loading…
Nov-06-25 05:07PM	Cerus: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance (Business Wire)
Oct-21-25 08:30AM	Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting (Business Wire)
Oct-16-25 04:00PM	Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Aug-25-25 09:00AM	The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions (Business Wire)
Aug-21-25 08:30AM	Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025 (Business Wire)
Aug-05-25 05:04PM	Cerus: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Cerus Corporation Announces Second Quarter 2025 Financial Results (Business Wire)
Aug-04-25 10:06AM	Cerus Corp (CERS) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-22-25 04:15PM	Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025 (Business Wire)
08:30AM	Loading…
Jul-21-25 08:30AM	Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury (Business Wire)
Jul-02-25 08:30AM	Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update (Business Wire) +5.41%
Jun-13-25 04:01PM	Cerus Corporation Celebrates World Blood Donor Day 2025 (Business Wire) +6.82%
Jun-03-25 04:30PM	Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Business Wire) +9.09%
May-29-25 08:30AM	Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan (Business Wire)
May-28-25 08:30AM	Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 Next-Generation INTERCEPT Illumination Device (Business Wire)
May-01-25 08:26PM	Cerus Corporation (CERS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:05PM	Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Cerus: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces First Quarter 2025 Financial Results (Business Wire)
Apr-17-25 08:30AM	Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025 (Business Wire)
Mar-06-25 11:44AM	Cerus secures CE mark approval for LED-based illumination device (Medical Device Network)
Mar-05-25 01:00PM	Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200) (Business Wire)
Feb-21-25 02:14AM	Cerus Corp (CERS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Cash Flow (GuruFocus.com) -5.17%
Feb-20-25 04:20PM	Cerus: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Loading…
04:00PM	Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results (Business Wire)
09:27AM	What To Expect From Cerus Corp (CERS) Q4 2024 Earnings (GuruFocus.com)
Feb-19-25 04:00PM	Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-07-25 08:30AM	Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025 (Business Wire)
Jan-13-25 08:30AM	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update (Business Wire) +5.70%
Nov-13-24 08:30AM	Cerus Corporation to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-24 02:11PM	Q3 2024 Cerus Corp Earnings Call (Thomson Reuters StreetEvents) -8.72%
05:01AM	Cerus Corp (CERS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Oct-30-24 05:10PM	Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:06PM	Cerus: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Third Quarter 2024 Financial Results (Business Wire)
Oct-29-24 09:16AM	Cerus Corp (CERS) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-18-24 08:30AM	Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024 (Business Wire)
08:30AM	Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting (Business Wire)
08:25AM	Cerus price target lowered to $3 from $6 at Stifel (TipRanks)
Oct-16-24 04:00PM	Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe (Business Wire) -9.44%
Oct-09-24 03:49PM	Cerus Corp (CERS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive EBITDA (GuruFocus.com) +8.72%
Sep-06-24 01:47AM	Insider Selling: CFO Kevin Green Sells 82,657 Shares of Cerus Corp (CERS) (GuruFocus.com)
Aug-01-24 05:10PM	Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.73% +14.95%
04:07PM	Cerus: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range (Business Wire)
Jul-18-24 08:30AM	Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire) -6.36%
Jul-02-24 04:00PM	Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors (Business Wire)
Jun-21-24 08:30AM	Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion (Business Wire)
Jun-14-24 08:30AM	Cerus Corporation Celebrates World Blood Donor Day 2024 (Business Wire)
May-22-24 08:30AM	Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference (Business Wire)
May-03-24 10:40AM	Cerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call Transcript (Insider Monkey) -7.95%
06:48AM	Q1 2024 Cerus Corp Earnings Call (Thomson Reuters StreetEvents)
03:58AM	Cerus Corp (CERS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-02-24 08:59PM	CERS Stock Earnings: Cerus Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:04PM	Cerus Corp (CERS) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows (GuruFocus.com)
04:04PM	Cerus: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces First Quarter 2024 Financial Results (Business Wire)
Apr-18-24 08:30AM	Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024 (Business Wire)
Mar-26-24 08:30AM	Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets Doubling Previous Shelf Life (Business Wire)
Mar-19-24 08:00AM	Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients (Business Wire) +9.68%
Mar-15-24 01:49AM	Insider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS) (GuruFocus.com)
01:48AM	Insider Sell: COO Vivek Jayaraman Sells 53,041 Shares of Cerus Corp (CERS) (GuruFocus.com)
Mar-07-24 01:40PM	Cerus Corp (CERS) Posts Narrowed Q4 Net Loss and Achieves Adjusted EBITDA Breakeven (GuruFocus.com)
11:46AM	Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 06:23AM	Q4 2023 Cerus Corp Earnings Call (Thomson Reuters StreetEvents) +21.61%
Mar-05-24 09:53PM	CERS Stock Earnings: Cerus Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) -6.13%
04:26PM	Cerus: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-23-24 11:56AM	12 Best Rising Penny Stocks To Buy (Insider Monkey)
Feb-20-24 08:30AM	Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024 (Business Wire)
Feb-01-24 08:30AM	Cerus Corporation to Participate in Upcoming Investor Conferences (Business Wire) +8.84%
Jan-15-24 09:30AM	3 Growth Stocks That Could Go Parabolic in 2024 (Motley Fool)
Jan-08-24 08:30AM	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update (Business Wire) +5.61%
Nov-03-23 09:19AM	Cerus Corporation (NASDAQ:CERS) Q3 2023 Earnings Call Transcript (Insider Monkey) +8.81%
08:30AM	Cerus Corporation to Participate in Upcoming Investor Conferences (Business Wire)
Nov-02-23 06:43PM	Cerus Corp (CERS) Q3 2023 Earnings: Product Revenue Stable, Operating Expenses Decrease by 4% (GuruFocus.com) +15.22%
05:25PM	Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:20PM	Cerus: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Third Quarter 2023 Financial Results (Business Wire)
Oct-19-23 08:30AM	Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023 (Business Wire)
Oct-10-23 08:30AM	Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting (Business Wire) +8.02%
Sep-27-23 08:30AM	Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer (Business Wire)
Sep-12-23 08:30AM	Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference (Business Wire)
Aug-02-23 05:15PM	Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -17.98%
04:11PM	Cerus: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 12:36PM	Cerus (NASDAQ:CERS) investors are sitting on a loss of 60% if they invested three years ago (Simply Wall St.)
Jul-19-23 08:30AM	Cerus Corporation to Release Second Quarter 2023 Financial Results on August 2, 2023 (Business Wire) +5.42%
Jul-03-23 05:13PM	12 Best NASDAQ Penny Stocks to Buy (Insider Monkey) -7.76%
Jun-15-23 08:30AM	Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress (Business Wire)
Jun-14-23 08:30AM	Cerus Corporation Celebrates World Blood Donor Day 2023 (Business Wire)
Jun-07-23 10:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Jun-05-23 08:30AM	Cerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate (Business Wire)
May-30-23 07:16AM	With 72% institutional ownership, Cerus Corporation (NASDAQ:CERS) is a favorite amongst the big guns (Simply Wall St.) +5.70%

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jensen Chrystal	Chief Legal Officer	Nov 24 '25	Sale	1.70	55,000	93,500	728,294	Nov 26 04:07 PM
CHRYSTAL NIKOLE JENSEN	Officer	Nov 24 '25	Proposed Sale	1.70	55,000	93,500		Nov 24 05:17 PM
Gregory Dean A.	Director	Aug 25 '25	Buy	1.25	25,000	31,250	86,725	Aug 25 03:25 PM
Jensen Chrystal	Chief Legal Officer	Mar 14 '25	Sale	1.45	30,075	43,609	783,294	Mar 17 05:02 PM
Jensen Chrystal	Chief Legal Officer	Mar 13 '25	Sale	1.45	18,949	27,476	813,369	Mar 17 05:02 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 14 '25	Sale	1.45	46,004	66,706	1,431,326	Mar 17 05:01 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 13 '25	Sale	1.45	29,985	43,478	1,477,330	Mar 17 05:01 PM
Greenman William Mariner	President and CEO	Mar 14 '25	Sale	1.45	122,827	178,099	4,115,845	Mar 17 05:00 PM
Greenman William Mariner	President and CEO	Mar 13 '25	Sale	1.45	71,086	103,075	4,238,672	Mar 17 05:00 PM
Green Kevin Dennis	Chief Financial Officer	Mar 14 '25	Sale	1.45	36,740	53,273	875,867	Mar 17 04:56 PM
Green Kevin Dennis	Chief Financial Officer	Mar 13 '25	Sale	1.45	23,147	33,563	912,607	Mar 17 04:56 PM
Benjamin Richard J	Chief Medical Officer	Mar 14 '25	Sale	1.45	30,075	43,609	685,775	Mar 17 04:55 PM
Benjamin Richard J	Chief Medical Officer	Mar 13 '25	Sale	1.45	18,949	27,476	715,850	Mar 17 04:55 PM
Jensen Chrystal	Chief Legal Officer	Mar 07 '25	Sale	1.50	27,457	41,131	832,318	Mar 10 07:59 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 07 '25	Sale	1.50	33,999	50,931	1,507,315	Mar 10 07:56 PM
Greenman William Mariner	President and CEO	Mar 07 '25	Sale	1.50	60,984	91,354	4,309,758	Mar 10 07:55 PM
Green Kevin Dennis	Chief Financial Officer	Mar 07 '25	Sale	1.50	31,148	46,660	935,754	Mar 10 07:54 PM
Benjamin Richard J	Chief Medical Officer	Mar 07 '25	Sale	1.50	26,139	39,156	734,799	Mar 10 07:53 PM
Jensen Chrystal	Chief Legal Officer	Mar 04 '25	Sale	1.58	66,292	104,885	405,198	Mar 05 08:31 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 04 '25	Sale	1.55	10,780	16,693	905,828	Mar 05 08:30 PM
Greenman William Mariner	President and CEO	Mar 04 '25	Sale	1.55	23,023	35,651	3,230,000	Mar 05 08:29 PM
Green Kevin Dennis	Chief Financial Officer	Mar 03 '25	Sale	1.58	60,656	95,673	493,862	Mar 05 08:27 PM
Green Kevin Dennis	Chief Financial Officer	Mar 04 '25	Sale	1.55	8,386	12,986	554,518	Mar 05 08:27 PM
Benjamin Richard J	Chief Medical Officer	Mar 03 '25	Sale	1.58	51,254	80,828	400,665	Mar 05 08:23 PM
Benjamin Richard J	Chief Medical Officer	Mar 04 '25	Sale	1.55	6,292	9,743	394,373	Mar 05 08:23 PM
Jensen Chrystal	Officer	Mar 04 '25	Proposed Sale	1.50	60,000	90,000		Mar 04 04:55 PM
RICHARD J BENJAMIN	Officer	Mar 03 '25	Proposed Sale	1.58	51,254	80,822		Mar 03 05:22 PM
KEVIN D GREEN	Officer	Mar 03 '25	Proposed Sale	1.58	60,656	95,646		Mar 03 04:56 PM

CORT

Corcept Therapeutics Inc

CERS

Cerus Corp

Upgrade your FINVIZ experience